Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Currently, many investors, including us, believe that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Vera Therapeutics Q: What did Vera Therapeutics announce on May 6th that is more than what we knew before? A: On May 6th Vera Therapeutics (VERA) provided business Update and Reported First Quarter 2025 Financial Results on track to announce the primary endpoint results from the atacicept pivotal . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Exelixis in the NEWS Two days ago, Exelixis (EXEL) reported financial results for the first quarter of 2025, providing an update on the firm’s progress toward achieving key corporate objectives, and outlined its commercial, clinical, and pipeline development milestones. From Exelixis Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis said, " Exelixis has delivered outstanding financial performance . . . This content is …
Yesterday's Market and CytomX Therapeutics May 12, 2025 was an excellent day for many stressed countries. The good day began following the U.S. and China’s announcement of an agreement on Tariffs Many countries have been stressed since being attacked by COVID-19 and then the war in Europe and the Middle East as well as unparallelled inflations. Yesterday, the Stock market rallied and with it …
PTC Therapeutics On May 6, 2025, PTC Therapeutics (PTCT) announced a corporate update and financial results for the first quarter ended March 31, 2025. We loved the firm’s strong revenue performance of $190 million, the positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, and, important is the NDA review remained on track for July 29, 2025, PDUFA date, the . . . This …
Alnylam Pharmaceuticals Synopsis Today, May 1, 2025 - Alnylam Pharmaceuticals (ALNY), the leading RNAi therapeutics company reported its consolidated financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights. From Alnylam Pharmaceuticals Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam Pharmaceuticals, said, “2025 is off to a remarkable start, having ended the first quarter with U.S . . . This …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
